Skip to main content

Neomycin and Polymyxin B Sulfates and Bacitracin Zinc

Generic: Neomycin sulfate, Polymyxin B Sulfate and Bacitracin Zinc

Verified·Apr 23, 2026
Manufacturer
Bausch Lomb
NDC
24208-780
RxCUI
308493
Route
OPHTHALMIC
ICD-10 indication
L08.9

Affordability Check

How much will you actually pay for Neomycin and Polymyxin B Sulfates and Bacitracin Zinc?

In 30 seconds, see every legitimate way to afford Neomycin and Polymyxin B Sulfates and Bacitracin Zinc — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Neomycin and Polymyxin B Sulfates and Bacitracin Zinc

What is this medication? Neomycin and Polymyxin B Sulfates and Bacitracin Zinc is a triple antibiotic medication used to prevent and treat minor skin infections caused by small cuts, scrapes, or burns. This topical ointment works by stopping the growth of certain bacteria that can enter the body through damaged skin. It is intended for external use only and provides a protective barrier while the wound heals.

The medication contains three different antibiotics that work together to provide broad-spectrum coverage against a variety of bacteria. Bacitracin Zinc, Neomycin, and Polymyxin B each target different parts of the bacterial cell, such as the cell wall or protein synthesis, to effectively neutralize the threat of infection. This combination is typically applied to the affected area one to three times daily as directed by a healthcare provider or product labeling.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Neomycin and Polymyxin B Sulfates and Bacitracin Zinc. Official source: DailyMed (NLM) · Label effective Jan 2, 2025

Indications and usage
INDICATIONS AND USAGE Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.
Dosage and administration
DOSAGE AND ADMINISTRATION Apply the ointment topically into the conjunctival sac of the affected eye(s) every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.
Contraindications
CONTRAINDICATIONS Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is contraindicated in individuals who have shown hypersensitivity to any of its components.
Warnings
WARNINGS NOT FOR INJECTION INTO THE EYE Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal wound healing. Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually itching, reddening, and edema of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Application of products containing these ingredients should be avoided for the patient thereafter ( see PRECAUTIONS: General ).
Adverse reactions
ADVERSE REACTIONS Adverse reactions have occurred with the anti-infective components of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including itching, swelling, and conjunctival erythema ( see WARNINGS ). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. Local irritation on instillation has also been reported. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Use in pregnancy
Pregnancy

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Neomycin and Polymyxin B Sulfates and Bacitracin Zinc appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

70%

3,881 of 5,509 plans

Most common tier

Tier 3

On 38% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)67
21%
Tier 2 (generic)113
36%
Tier 3 (preferred brand)121
38%
Tier 4 (non-preferred brand)17
5%

Step therapy: 0% of formularies

Quantity limits: 10% of formularies

Coverage breadth: 318 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.